Diana L. Hanna

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton et al. · The Lancet Oncology · 2022 · 164 citations · Full text

Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis

Dongyun Yang, Diana L. Hanna, J. R. Usher et al. · Cancer · 2014 · 137 citations · Full text

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

Funda Meric‐Bernstam, M. Beeram, José Mayordomo et al. · Journal of Clinical Oncology · 2018 · 83 citations

Her2-targeted Bispecific Antibody, Breast Oncology, Immunology +24

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

Funda Meric‐Bernstam, Diana L. Hanna, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2021 · 67 citations

Cancer Management, Pathology, Btc Patients +16

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers

Brandon M. Huffman, Vasily N. Aushev, Griffin Budde et al. · JCO Precision Oncology · 2022 · 63 citations · Full text